Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study

At Week 96 of the Single-Tablet Regimen (STaR) study, more treatment-naïve subjects that received rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF) developed resistance mutations compared to those treated with efavirenz (EFV)/FTC/TDF by population sequencing. Furthermore, more RPV/FTC/TDF-treated...

Descripción completa

Detalles Bibliográficos

Autores principales:	Danielle P. Porter, Martin Daeumer, Alexander Thielen, Silvia Chang, Ross Martin, Cal Cohen, Michael D. Miller, Kirsten L. White
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2015-12-01
Colección:	Viruses
Materias:	rilpivirine efavirenz resistance virologic failure minority variants
Acceso en línea:	http://www.mdpi.com/1999-4915/7/12/2943
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!